JP2023549851A5 - - Google Patents

Info

Publication number
JP2023549851A5
JP2023549851A5 JP2023528641A JP2023528641A JP2023549851A5 JP 2023549851 A5 JP2023549851 A5 JP 2023549851A5 JP 2023528641 A JP2023528641 A JP 2023528641A JP 2023528641 A JP2023528641 A JP 2023528641A JP 2023549851 A5 JP2023549851 A5 JP 2023549851A5
Authority
JP
Japan
Prior art keywords
seq
sequence
cdr1
cdr2
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023528641A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549851A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/059701 external-priority patent/WO2022109010A1/en
Publication of JP2023549851A publication Critical patent/JP2023549851A/ja
Publication of JP2023549851A5 publication Critical patent/JP2023549851A5/ja
Pending legal-status Critical Current

Links

JP2023528641A 2020-11-18 2021-11-17 葉酸受容体アルファに結合する重鎖抗体 Pending JP2023549851A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063115436P 2020-11-18 2020-11-18
US63/115,436 2020-11-18
PCT/US2021/059701 WO2022109010A1 (en) 2020-11-18 2021-11-17 Heavy chain antibodies binding to folate receptor alpha

Publications (2)

Publication Number Publication Date
JP2023549851A JP2023549851A (ja) 2023-11-29
JP2023549851A5 true JP2023549851A5 (cg-RX-API-DMAC7.html) 2024-11-25

Family

ID=79024440

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023528641A Pending JP2023549851A (ja) 2020-11-18 2021-11-17 葉酸受容体アルファに結合する重鎖抗体

Country Status (18)

Country Link
US (1) US20240002498A1 (cg-RX-API-DMAC7.html)
EP (1) EP4247498A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023549851A (cg-RX-API-DMAC7.html)
KR (1) KR20230110303A (cg-RX-API-DMAC7.html)
CN (1) CN116615253A (cg-RX-API-DMAC7.html)
AR (1) AR124084A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021383743A1 (cg-RX-API-DMAC7.html)
CA (1) CA3199785A1 (cg-RX-API-DMAC7.html)
CL (2) CL2023001432A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023006790A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230259A (cg-RX-API-DMAC7.html)
IL (1) IL302670A (cg-RX-API-DMAC7.html)
JO (1) JOP20230109A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023005693A (cg-RX-API-DMAC7.html)
PE (1) PE20231203A1 (cg-RX-API-DMAC7.html)
TW (1) TW202233684A (cg-RX-API-DMAC7.html)
UY (1) UY39522A (cg-RX-API-DMAC7.html)
WO (1) WO2022109010A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109862784A (zh) 2016-08-24 2019-06-07 特尼奥生物股份有限公司 产生经修饰的仅有重链的抗体的转基因非人动物
EP3559035A1 (en) 2016-12-21 2019-10-30 TeneoBio, Inc. Anti-bcma heavy chain-only antibodies
EA202091557A1 (ru) 2017-12-22 2020-11-18 Тенеобио, Инк. Антитела, содержащие только тяжелые цепи, которые связываются с cd22
CA3133654A1 (en) 2019-04-05 2020-10-08 Teneobio, Inc. Heavy chain antibodies binding to psma
CN114206927B (zh) 2019-06-14 2025-03-21 特尼奥生物股份有限公司 与cd22和cd3结合的多特异性重链抗体
EP4577576A4 (en) * 2022-08-22 2026-08-12 Abdera Therapeutics Inc KIDNEY-TARGETING ANTIBODIES
TW202608930A (zh) * 2024-06-05 2026-03-01 大陸商長春金賽藥業有限責任公司 靶向葉酸受體α(FRα)的抗體、雙特異性抗體和偶聯物,及其製備和用途
WO2026133379A1 (en) * 2024-12-20 2026-06-25 Fondazione Irccs Istituto Nazionale Dei Tumori Bispecific antibodies directed against alpha-folate receptor

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
MXPA05004677A (es) 2002-10-31 2005-11-17 Genentech Inc Metodos y composiciones para aumentar la produccion de anticuerpos.
WO2004065417A2 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
EP1776383B1 (en) 2004-07-22 2014-08-20 Erasmus University Medical Center Rotterdam Binding molecules
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
CN102421801B (zh) 2009-03-10 2016-03-16 比奥根Ma公司 抗-bcma抗体
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
US20140308285A1 (en) * 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
SG11201704056XA (en) * 2014-11-20 2017-06-29 Hoffmann La Roche Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists
RS61010B1 (sr) * 2014-11-20 2020-11-30 Hoffmann La Roche Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3
IL299221A (en) 2016-06-21 2023-02-01 Teneobio Inc Cd3 binding antibodies
CN109862784A (zh) 2016-08-24 2019-06-07 特尼奥生物股份有限公司 产生经修饰的仅有重链的抗体的转基因非人动物
CR20220578A (es) 2016-09-14 2023-01-17 Teneobio Inc Anticuerpos de unión a cd3
EP3765521A4 (en) * 2018-03-13 2022-03-23 Phanes Therapeutics, Inc. ANTI-FOLATE RECEPTOR-1 ANTIBODIES AND USES THEREOF
CA3133654A1 (en) * 2019-04-05 2020-10-08 Teneobio, Inc. Heavy chain antibodies binding to psma

Similar Documents

Publication Publication Date Title
JP2022061992A5 (cg-RX-API-DMAC7.html)
TWI821474B (zh) Cd3抗體及其藥物用途
JP6719477B2 (ja) 抗tim−3抗体
JP2023509448A5 (cg-RX-API-DMAC7.html)
JP2019536430A5 (cg-RX-API-DMAC7.html)
JP2021534762A5 (cg-RX-API-DMAC7.html)
RU2019128134A (ru) Антитело против gprc5d и молекула, содержащая антитело
JP2023538945A5 (cg-RX-API-DMAC7.html)
JP2019501883A5 (cg-RX-API-DMAC7.html)
JP2022504802A5 (cg-RX-API-DMAC7.html)
JP2019532625A5 (cg-RX-API-DMAC7.html)
WO2018137576A1 (zh) 抗pd-1单克隆抗体及其制备方法和应用
JP2021510521A5 (cg-RX-API-DMAC7.html)
JP2018527919A5 (cg-RX-API-DMAC7.html)
JP2023551027A5 (cg-RX-API-DMAC7.html)
JP2010535012A5 (cg-RX-API-DMAC7.html)
JP2021511811A5 (cg-RX-API-DMAC7.html)
JP2022551836A (ja) Bcmaを標的とする抗体、二重特異性抗体及びその用途
JP2022521705A5 (cg-RX-API-DMAC7.html)
JP2012501670A5 (cg-RX-API-DMAC7.html)
JP2023548529A5 (cg-RX-API-DMAC7.html)
JP2021510736A5 (cg-RX-API-DMAC7.html)
JP2021520832A5 (cg-RX-API-DMAC7.html)
JP2018505681A5 (cg-RX-API-DMAC7.html)
RU2007145419A (ru) Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами